Rare disease biotech Electra picks commercially-minded Kathy Dong as next CEO
Electra Therapeutics is several years away from having a commercial product. And yet, the biotech’s new CEO Kathy Dong’s resume is stacked with experience on marketing and launching drugs—most notably, Gilead’s Sovaldi and Harvoni.
Electra Therapeutics presents first clinical data from ongoing Phase 1b study of ELA026 for treatment of secondary hemophagocytic lymphohistiocytosis (sHLH)
SOUTH SAN FRANCISCO, CA, December 11, 2023 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, announced the presentation of the first clinical data for ELA026…
Electra Therapeutics Appoints Kathy Dong, PharmD, MBA, as President and Chief Executive Officer
SOUTH SAN FRANCISCO, CA, December 11, 2023 – Electra Therapeutics, a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced the appointment of Kathy Dong, PharmD, MBA, as President and…
